Oncology clinical development: Optimizing value through implementation of a patient-centric, holistic endpoint strategy
Oncology clinical trials are constantly evolving, placing greater demands on development teams to generate high-quality, patient-centered data that meet the expectations of regulators, clinicians, payers and patients alike.
In this upcoming webinar, scientific specialists will share how a holistic endpoint strategy spanning electronic clinical outcome assessment (eCOA), cardiac safety and medical imaging can strengthen trial outcomes, accelerate development and enhance patient impact. Attendees will gain practical insights into building an integrated approach that captures meaningful endpoints, supports regulatory success and maximizes the value of oncology programs from early to late phase.
Register for this webinar now to learn how an integrated endpoint strategy can drive better outcomes in oncology clinical development.
Session information:
Time:
- 11:00 a.m. – 12:00 p.m. EDT (NA-East)
- 16:00 – 17:00 BST (UK)
- 17:00 – 18:00 CEST (EU-Central)
Attendees will learn how early implementation of eCOA, in alignment with the latest FDA guidance, ensures regulatory compliance while capturing meaningful patient-reported outcomes, helping to differentiate a drug.
The webinar will also address key cardiac safety considerations, including ECG best practices for QT assessment, the role of cardiac imaging and blood pressure monitoring to detect early signs of treatment-related risk.
In addition, the session will highlight the impact of centralized imaging in oncology trials, offering greater consistency and reduced bias versus site-based assessments. Attendees will discover how to optimize data quality and support informed decision-making in oncology clinical trials.
Register for this webinar now to learn how an integrated endpoint strategy can drive better outcomes in oncology clinical development.
Speakers
Todd Rudo, M.D.
EVP and Chief Medical Officer at Clario
Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety.
Dr. Rudo has board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, adult echocardiography and internal medicine. His team provides expert consulting to clients on scientific and regulatory strategy and ensures Clario’s product portfolio is scientifically robust, generating high-quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.
Thomas Moll, Ph.D., MBA
Senior Scientific Advisor at Clario
Dr. Thomas Moll has been working in the life sciences industry for more than 20 years and has held various positions both in the CRO space and within big pharma (Eli Lilly). Over the years, one of his areas of focus has been post-marketing projects that require patient experience data for regulatory decision making, be it as a regulatory writer or coordinating large global Phase IV studies. Since joining Clario as a Scientific Advisor eCOA in 2022, he participates in numerous new initiatives aimed at strengthening the role of science throughout the eCOA lifecycle to improve data integrity and ultimately patients’ benefit. In addition, he’s passionate about transmitting his knowledge about the exciting world of drug development to young professionals.
Fabian Chen, M.D., Ph.D.
VP and Deputy CMO, Cardiology at Clario
Dr. Fabian Chen is Deputy Chief Medical Officer – Cardiology and Vice President at Clario. In addition to providing leadership for Clario’s Cardiac Safety department, Dr. Chen provides expert consultation to clients on scientific and regulatory strategy. Dr. Chen has nearly 20 years of clinical cardiology and pharmaceutical research experience. Recent positions include Chief Medical Officer at the University of Pennsylvania Gene Therapy Program and Vice President of Clinical Development at Rocket Pharmaceuticals. Dr. Chen also has over 10 years of experience in both early and late-stage clinical development working at Merck and Novartis Pharmaceuticals.
Fabian received his undergraduate degree at Harvard College and his M.D. Ph.D. at Yale University. He completed his internal medicine and cardiology training at the University of Pennsylvania School of Medicine. Prior to entering the pharmaceutical industry, Fabian was a faculty member of the departments of Medicine, Pediatrics and Molecular & Cellular Physiology at the University of California, Los Angeles.
Anu Bansal M.D., MS
VP, Medical Imaging Oncology at Clario
As Vice President of Imaging in oncology, Dr. Anu Bansal provides leadership and oversight of all aspects of Imaging in Phase I to Phase IV drug and device trials from protocol design through registrational submission and post-approval monitoring. He uses his 20+ years of experience in clinical research and patient care to support Clario’s cross-functional teams and clients in medical, regulatory and scientific affairs.
Dr. Bansal trained and has board certifications in diagnostic radiology, diagnostic and interventional neuroradiology and clinical informatics. He received his undergraduate degree in Biochemistry from Harvard University, his M.D. from the Albert Einstein College of Medicine and an MS in Healthcare Management from the Harvard School of Public Health. He completed residency training at Brigham and Women’s Hospital and his fellowships at the Mallinckrodt Institute of Radiology at Washington University.